Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShort-Term Debt repayments
Ratios

Myriad Genetics (MYGN) Accumulated Depreciation & Amortization (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Accumulated Depreciation & Amortization for 16 consecutive years, with $87.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Accumulated Depreciation & Amortization fell 19.8% to $87.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $87.9 million, a 19.8% decrease, with the full-year FY2025 number at $87.9 million, down 19.8% from a year prior.
  • Accumulated Depreciation & Amortization was $87.9 million for Q4 2025 at Myriad Genetics, up from $83.3 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $119.9 million in Q4 2023 to a low of $79.4 million in Q2 2025.
  • A 5-year average of $103.9 million and a median of $108.5 million in 2022 define the central range for Accumulated Depreciation & Amortization.
  • Peak YoY movement for Accumulated Depreciation & Amortization: grew 9.8% in 2023, then fell 28.99% in 2025.
  • Myriad Genetics' Accumulated Depreciation & Amortization stood at $106.9 million in 2021, then increased by 2.15% to $109.2 million in 2022, then rose by 9.8% to $119.9 million in 2023, then fell by 8.59% to $109.6 million in 2024, then dropped by 19.8% to $87.9 million in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Accumulated Depreciation & Amortization are $87.9 million (Q4 2025), $83.3 million (Q3 2025), and $79.4 million (Q2 2025).